MX2020006678A - Terapia para cancer. - Google Patents

Terapia para cancer.

Info

Publication number
MX2020006678A
MX2020006678A MX2020006678A MX2020006678A MX2020006678A MX 2020006678 A MX2020006678 A MX 2020006678A MX 2020006678 A MX2020006678 A MX 2020006678A MX 2020006678 A MX2020006678 A MX 2020006678A MX 2020006678 A MX2020006678 A MX 2020006678A
Authority
MX
Mexico
Prior art keywords
cancer
cancer therapeutic
phenylbenzoxazol
dichloro
tyrosine
Prior art date
Application number
MX2020006678A
Other languages
English (en)
Inventor
Hitoshi Endou
Junji Furuse
Isao Okayasu
Michael F Wempe
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Publication of MX2020006678A publication Critical patent/MX2020006678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

O-(5-amino-2-fenil benz oxazol-7-il)metil-3, 5-dicloro-L-tirosina o una sal farmacéuticament e aceptable de este exhibe efectos terapéuticos altos en cáncer de ductos biliares, cáncer colorrectal, cáncer esofágico, cáncer de mama, y cáncer pancreático.
MX2020006678A 2017-12-28 2018-08-01 Terapia para cancer. MX2020006678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017253385 2017-12-28
PCT/JP2018/028887 WO2019130637A1 (ja) 2017-12-28 2018-08-01 がん治療薬

Publications (1)

Publication Number Publication Date
MX2020006678A true MX2020006678A (es) 2020-08-31

Family

ID=67066788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006678A MX2020006678A (es) 2017-12-28 2018-08-01 Terapia para cancer.

Country Status (10)

Country Link
US (1) US20200405695A1 (es)
EP (1) EP3733175B1 (es)
JP (4) JP6546367B1 (es)
KR (1) KR102377742B1 (es)
CN (1) CN111491632A (es)
BR (1) BR112020012766A2 (es)
CA (1) CA3083343C (es)
ES (1) ES2960392T3 (es)
MX (1) MX2020006678A (es)
WO (1) WO2019130637A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3709021A4 (en) * 2017-11-07 2021-07-21 J-Pharma Co., Ltd. METHOD FOR PREDICTING THE EFFECTIVENESS OF ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY THERAPY, METHOD OF EVALUATING THE LEVEL OF CANCER AND METHOD OF IMPROVING THE EFFECTIVENESS OF ANTI-BODY THERAPY ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
AU2021207666A1 (en) * 2020-01-17 2022-09-01 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JPWO2022102687A1 (es) * 2020-11-11 2022-05-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
KR20170001962A (ko) * 2014-05-15 2017-01-06 제이 파마 가부시끼가이샤 항 악성 종양제 조성물
JP2017155023A (ja) 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤
EP3709021A4 (en) * 2017-11-07 2021-07-21 J-Pharma Co., Ltd. METHOD FOR PREDICTING THE EFFECTIVENESS OF ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY THERAPY, METHOD OF EVALUATING THE LEVEL OF CANCER AND METHOD OF IMPROVING THE EFFECTIVENESS OF ANTI-BODY THERAPY ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
JPWO2021040043A1 (es) * 2019-08-30 2021-03-04
JPWO2022102687A1 (es) * 2020-11-11 2022-05-19

Also Published As

Publication number Publication date
JP2019151672A (ja) 2019-09-12
EP3733175B1 (en) 2023-10-04
CN111491632A (zh) 2020-08-04
EP3733175A1 (en) 2020-11-04
JP6546367B1 (ja) 2019-07-17
BR112020012766A2 (pt) 2020-12-01
CA3083343C (en) 2022-04-26
JP6734971B2 (ja) 2020-08-05
JP2023101705A (ja) 2023-07-21
EP3733175A4 (en) 2021-08-18
JP2020073586A (ja) 2020-05-14
ES2960392T3 (es) 2024-03-04
WO2019130637A1 (ja) 2019-07-04
CA3083343A1 (en) 2019-07-04
US20200405695A1 (en) 2020-12-31
KR102377742B1 (ko) 2022-03-22
JPWO2019130637A1 (ja) 2019-12-26
KR20200101960A (ko) 2020-08-28

Similar Documents

Publication Publication Date Title
MX2020006678A (es) Terapia para cancer.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019012532A (es) Moduladores de k-ras.
MX2017013075A (es) Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2.
MX2017014163A (es) Moduladores de k-ras.
MX2019003938A (es) Compuestos espirociclicos.
EA201991818A1 (ru) Лечение рака
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
GB201903546D0 (en) Cancer treatment
MX2017012553A (es) Compuestos espirociclicos.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
AU2018301651A1 (en) A peptide saporin conjugate for the treatment of cancer
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
IL285466A (en) Cancer treatment
IL267613A (en) Pancreatic cancer treatment
HK1257829A1 (zh) 移動消息源驗證
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
IL288035A (en) Cancer treatment
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
EP3966323A4 (en) TARGETED THERAPY
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
GB201913957D0 (en) Cancer
GB201819920D0 (en) Cancer treatment